Finally some positive news, great to hear. However the delivery could have been structured more positively, the old sh*& sandwich approach is tried and tested, hide the negative in the middle of the positives.
To be honest nobody expected the paediatric results to be anything but negative, we have all known for some time now that IMM-124E does not significantly change ALT in NASH patients. Hence why the entire arm of NASH/ASH has been abandoned. Personally I'm glad that bandaid has been ripped off and the whole NASH/ASH phase can be left behind.
Time to move on with the FDA approvals. I have always advocated that the true potential in this company is with IMM-529 and C. Diff. Hopefully at some stage that investigation will recommence.
To conclude the announcement, it could have been strengthened by restating that the IND with the FDA re. IMM-124E and IMM-529 is still a priority and will be progressing once again as the pandemic eases, give some sort of time frame, if known.
Oh well what can you expect from a bunch of scientists. Immuron is in desperate need of a true dedicated business strategist.
Ann: US Defense requests FDA meeting, page-2
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.79M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $7.213K | 72.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20524 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 167832 | 5 |
View Market Depth
| Last trade - 15.57pm 19/07/2024 (20 minute delay) ? |
| IMC (ASX) Chart |